LENZ Therapeutics (LENZ) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on LENZ Therapeutics (LENZ) is Moderate Underperform.

The composite score behind that read is -0.51, weighing +0.00 of bullish evidence against -0.50 bearish.

LENZ Therapeutics last closed at $3.62, -4.49% on the session.

Against the IVW growth benchmark the position is -4.33% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

18 graded predictions for LENZ so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks LENZ Therapeutics in the 17th percentile on return on equity, where 100 is best.

LENZ Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $119.08M.

StockMap tracks LENZ Therapeutics as the 98th largest of the 149 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 62 Moderate Underperform, 59 Neutral, 21 Strong Underperform and 7 Moderate Outperform.

On that composite LENZ Therapeutics ranks 127th of 149 in the group, against a group median of -0.27.